Citations

Showing 10 of 108104 citations.

HLA‐B*45:22: a novel allele that differs from HLA‐B*45:01:01 at several locations
Dukek, Brian A. , Zuccarelli, Micah D., Wakefield, Laurie L., Kreuter, Justin D. , Gandhi, Manish J.

Mayo Clinic

HLA | November 13, 2018 | Volume: 93 | Issue: 1 | Pages: 49-50

10.1111/tan.13422 | PMID 30421561 Get It

Discovery of a novel HLA‐B*45:22 allele in a Middle Eastern heart and lung transplant candidate.
A Real‐time Color Doppler Marker for Echocardiographic Guidance of an Acoustically Active Extracorporeal Membrane Oxygenation Cannula
Bëlohlávek, Marek , Vaitkus, Veronica V. , Fatemi, Mostafa , Grabham, Jason, Sandweiss, Bryan M., Katayama, Minako , Kumar, Viksit, Fatemi, Mostafa , Kumar, Viksit

Mayo Clinic

Journal of Ultrasound in Medicine | November 12, 2018 | Volume: 38 | Issue: 7 | Pages: 1875-1885

10.1002/jum.14859 | PMID 30419612 Get It

B‐mode ultrasound imaging guidance of cannulas can be compromised by noise, artifacts, and echogenicity that is not distinctive from that of surrounding anatomy. We have modified a venovenous extracorporeal membrane oxygenation cannula by embedding piezoelectric crystals into each of its 3 blood flow ports. Each vibrating crystal acoustically interacts with a Doppler imaging signal and produces an instantaneous color marker. The aim of this study was to compare identification of the extracorporeal membrane oxygenation cannula ports by B‐mode imaging versus the color Doppler marker. Unlike B‐mode imaging, the color Doppler marker identified the corresponding port even in highly challenging closed‐chest scans in anesthetized pigs. The method could improve guidance accuracy of cannulas by ultrasound scans.
Validity and Responsiveness of the Single Alpha-numeric Evaluation for Shoulder Patients
Shanley, Ellen , Momaya, Amit , Kissenberth, Michael J. , Tolan, Stefan J., Tokish, John M. , Hawkins, Richard J. , Thigpen, Charles A.

Mayo Clinic

The American Journal of Sports Medicine | November 12, 2018 | Volume: 46 | Issue: 14 | Pages: 3480-3485

10.1177/0363546518807924 | PMID 30419173 Get It

Background: There is an ever-increasing demand for widespread implementation of patient-reported outcomes. However, adoption is slow owing to limitations in clinical infrastructure and resources within busy orthopaedic practices. Prior studies showed the single alpha-numeric evaluation (SANE) score to correlate at a single point in time with the American Shoulder and Elbow Surgeons (ASES) score. However, no study has validated the SANE in terms of test-retest reliability, responsiveness, or clinical utility. Purpose: To validate SANE with the ASES across a sample of patients with common orthopaedic shoulder diagnoses. Study Design: Cohort study (diagnosis); Level of evidence, 2. Methods: Patients undergoing rotator cuff repair (n = 77), total shoulder replacement (n = 55), or physical therapy (n = 80) for signs and symptoms of subacromial impingement syndrome (n = 61) or adhesive capsulitis (n = 19) were administered the SANE and ASES at baseline and again at their 3-month follow-up from initial care or surgery (N = 212, mean ± SD age = 52.6 ± 1.2 years, n = 145 women). Interclass correlation coefficient (ICC 2,1 ) and standard error of the measurement (SEm) were used to evaluate the test-retest reliability of the SANE and the validity between the SANE and ASES scores. Analysis of variance (treatment group × time) was used to evaluate the responsiveness to treatment, and a receiver operating characteristic curve was used to establish the minimal clinically important difference (MCID) for the SANE as compared with the ASES (α = .05). Floor and ceiling effects were evaluated as the percentage of patients who scored the highest or lowest score on each tool. Results: The SANE demonstrated good pretreatment reliability (ICC 2,1 = 0.84, SEM = 3.8), similar to the ASES (ICC 2,1 = 0.82, SEM = 3.4). The SANE also showed good agreement with the ASES before and after treatment across all treatment groups (rotator cuff repair, ICC 2,1 = 0.85, SEM = 3.4; total shoulder replacement, ICC 2,1 = 0.72, SEM = 5.2; physical therapy: ICC 2,1 = 0.82, SEM = 2.9). The SANE and ASES displayed similar responsiveness after treatment, with similar mean change and SD within each treatment group. The receiver operating characteristic curve revealed an area under the curve of 0.79 (SE, 0.62; P < .001) and a cutoff of 15% on the SANE, with a sensitivity of 85% to establish the MCID. Acceptable and similar floor and ceiling effects were observed for the ASES (4%) and SANE (9%). Conclusion: The study demonstrates that the SANE is valid for a range of common shoulder diagnoses to assess patient outcomes across operative and nonoperative treatment for shoulder complaints. The MCID of 15% is similar to that of the ASES (11%), suggesting that the SANE is a simple and efficient tool to assess treatment effects for shoulder disorders. Future studies are warranted to confirm these results and compare across other body parts and diagnoses.
Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer
Gerke, Travis , Beltran, Himisha , Lee, Gwo‐Shu Mary , Karnes, R. Jeffrey , Klein, Eric A. , Davicioni, Elai , Yousefi, Kasra, Ross, Ashley E. , Börnigen, Daniela , Mucci, Lorelei A. , Sweeney, Christopher J. , Davicioni, Elai , Klein, Eric A , Sweeney, Christopher , Wang, Xiaodong , Sboner, Andrea , Huttenhower, Curtis , Trock, Bruce J

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 12, 2018 | Volume: 28 | Issue: 3 | Pages: 584-590

10.1158/1055-9965.epi-18-0667 | PMID 30420441 Get It

Abstract Background: Inflammation is linked to prostate cancer progression and is mediated by NF-κB. Tristetraprolin is a key node of NF-κB activation and we investigated its biological and prognostic role in lethal prostate cancer. Methods: In vitro assays assessed the function of tristetraprolin and the association between low mRNA tristetraprolin levels and lethal prostate cancer (metastatic disease or death) was assessed across independent prostatectomy cohorts: (i) nested case-control studies from Health Professionals Follow-up Study and Physicians’ Health Study, and (ii) prostatectomy samples from Cleveland Clinic, Mayo Clinic, Johns Hopkins and Memorial Sloan Kettering Cancer Center. Tristetraprolin expression levels in prostatectomy samples from patients with localized disease and biopsies of metastatic castration–resistant prostate cancer (mCRPC) were assessed in a Cornell University cohort. Results: In vitro tristetraprolin expression was inversely associated with NF-κB–controlled genes, proliferation, and enzalutamide sensitivity. Men with localized prostate cancer and lower quartile of tumor tristetraprolin expression had a significant, nearly two-fold higher risk of lethal prostate cancer after adjusting for known clinical and histologic prognostic features (age, RP Gleason score, T-stage). Tristetraprolin expression was also significantly lower in mCRPC compared with localized prostate cancer. Conclusions: Lower levels of tristetraprolin in human prostate cancer prostatectomy tissue are associated with more aggressive prostate cancer and may serve as an actionable prognostic and predictive biomarker. Impact: There is a clear need for improved biomarkers to identify patients with localized prostate cancer in need of treatment intensification, such as adjuvant testosterone suppression, or treatment de-intensification, such as active surveillance. Tristetraprolin levels may serve as informative biomarkers in localized prostate cancer.
Infographic: Replacing failed reverse shoulder arthroplasties as a reliable revision approach
Wagner, Eric R. , Cofield, Robert H. , Sperling, John W. , Wagner, Eric R , Hevesi, Mario , Houdek, Matthew T. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

The Bone & Joint Journal | November 12, 2018 | Volume: 100-B | Issue: 11 | Pages: 1491-1492

10.1302/0301-620x.100b11.bjj-2018-1139 | PMID 30418056 Get It

Irrigation and debridement with chronic antibiotic suppression for the management of infected total knee arthroplasty
Weston, John T., Mabry, Tad M. , Hanssen, Arlen D. , Berry, Daniel J. , Berry, Daniel J , Watts, Chad D. , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | November 12, 2018 | Volume: 100-B | Issue: 11 | Pages: 1471-1476

10.1302/0301-620x.100b11.bjj-2018-0515.r1 | PMID 30418067 Get It

AimsThe results of irrigation and debridement with component retention (IDCR) in the treatment of acutely infected total knee arthroplasties (TKAs) have been variable. The aim of this study was to assess the outcome after IDCR when combined with chronic antibiotic suppression. We also evaluated survivorship free from subsequent infection, removal of the components, and death, as well as the risk factors for failure.Patients and MethodsThis was a single-centre retrospective review of 134 infected primary TKAs that were treated with IDCR. Infections within four weeks of the procedure were defined as acute postoperative infections, and those occurring more than four weeks after the procedure with symptoms for less than three weeks were defined as acute haematogenous infections. Patients were treated with intravenous antibiotics for four to six weeks, followed by chronic oral antibiotic suppression. Estimates of survival were made using a competing risk analysis. The mean follow-up was five years (2.1 to 13).ResultsThe infection was an acute postoperative infection in 23 TKAs and an acute haematogenous infection in 111 TKAs. The incidence of subsequent infection was 36% in those with an acute postoperative infection and 33% in those with a haematogenous infection, five years postoperatively (p = 0.40). Age < 60 years increased the risk of subsequent infection (hazard ratio (HR) 2.4; p = 0.009) and removal of the components (HR 2.8; p = 0.007). Infection with a staphylococcal species increased the risk of subsequent infection (HR 3.6; p < 0.001), and removal of the components (HR 3.2; p = 0.002). Musculoskeletal Infection Society host type and local extremity grade, body mass index (BMI), the duration of symptoms, gender, and the presence of a monoblock tibial component had no significant effect on the outcome.ConclusionIn a rigorously defined group of acute periprosthetic infections after TKA treated with IDCR and chronic antibiotic suppression, the infection-free survival at five years was 66%. The greatest risk factor for failure was an infection with a staphylococcal species, followed by age of < 60 years. Cite this article: Bone Joint J 2018;100-B:1471–76.
Can a reverse shoulder arthroplasty be used to revise a failed primary reverse shoulder arthroplasty?
Wagner, Eric R. , Cofield, Robert H. , Sperling, John W. , Wagner, Eric R , Hevesi, Mario , Houdek, Matthew T. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

The Bone & Joint Journal | November 12, 2018 | Volume: 100-B | Issue: 11 | Pages: 1493-1498

10.1302/0301-620x.100b11.bjj-2018-0226.r2 | PMID 30418055 Get It

Aims Patients with a failed reverse shoulder arthroplasty (RSA) have limited salvage options. The aim of this study was to determine the outcome of revision RSA when used as a salvage procedure for a failed primary RSA. Patients and Methods We reviewed all revision RSAs performed for a failed primary RSA between 2006 and 2012, excluding patients with a follow-up of less than two years. A total of 27 revision RSAs were included in the study. The mean age of the patients at the time of revision was 70 years (58 to 82). Of the 27 patients, 14 (52% were female). The mean follow-up was 4.4 years (2 to 10). Results Six patients (22%) developed complications requiring further revision surgery, at a mean of 1.7 years (0.1 to 5.3) postoperatively. The indication for further revision was dislocation in two, glenoid loosening in one, fracture of the humeral component in one, disassociation of the glenosphere in one, and infection in one. The five-year survival free of further revision was 85%. Five additional RSAs developed complications that did not need surgery, including dislocation in three and periprosthetic fracture in two. Overall, patients who did not require further revision had excellent pain relief, and significant improvements in elevation and external rotation of the shoulder (p < 0.01). The mean postoperative American Shoulder and Elbow Surgeons (ASES), and simple shoulder test (SST) scores were 66 and 7, respectively. Radiological results were available in 26 patients (96.3%) at a mean of 4.3 years (1.5 to 9.5). At the most recent follow-up, six patients (23%) had glenoid lucency, which were classified as grade III or higher in three (12%). Smokers had a significantly increased risk of glenoid lucency (p < 0.01). Conclusion Revision RSA, when used to salvage a failed primary RSA, can be a successful procedure. At intermediate follow-up, survival rates are reasonable, but dislocation and glenoid lucency remain a concern, particularly in smokers. Cite this article: Bone Joint J 2018;100-B:1493–98.
Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences
Wang, Tracy Y , Mi, Xiaojuan, Robinson, Jennifer G. , Roger, Véronique L. , Goldberg, Anne C. , Návar, Ann Marie , Virani, Salim S. , Wilson, Peter W.F. , Peterson, Eric D.

Mayo Clinic

JAMA Cardiology | November 12, 2018 | Volume: 3 | Issue: 12 | Pages: 1192

10.1001/jamacardio.2018.3680 | PMID 30419113 Get It

Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment
Kern, Silke , Syrjanen, Jeremy A. , Blennow, Kaj , Hagen, Clinton E., Harten, Argonde C. van , Jack, Clifford R. , Petersen, Ronald C. , Mielke, Michelle M. , van Harten, Argonde C, Jack, Clifford R , Mielke, Michelle M , Zetterberg, Henrik , Skoog, Ingmar , Wærn, Margda , Knopman, David S.

Mayo Clinic

JAMA Neurology | November 12, 2018 | Volume: 76 | Issue: 2 | Pages: 187

10.1001/jamaneurol.2018.3459 | PMID 30419087 Get It

Introduction of novel agents in the treatment of primary CNS lymphoma
Grommes, Christian , Nayak, Lakshmi , Batchelor, Tracy T. , Tun, Han W.

Mayo Clinic

Neuro-Oncology | November 12, 2018 | Volume: 21 | Issue: 3 | Pages: 306-313

10.1093/neuonc/noy193 | PMID 30423172 Get It